About the Authors
- Keiji Nishiyama
-
Affiliation CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa, Japan
- Keisuke Hirai
-
* E-mail: keisuke.hirai@takeda.com
Affiliation CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd., Fujisawa, Kanagawa, Japan
Competing Interests
The authors have the following interests. This study was supported by Takeda Pharmaceutical Company Ltd. The publication steering committee of Takeda Pharmaceutical Company Ltd. played a role in the decision to Cover Letter publish. One of the authors, Keisuke Hirai, is a senior director of Takeda, and is a member of the committee and is responsible for the decision on the present publication. Keiji Nishiyama is employed by Takeda Pharmaceutical Company. The study used a marketed product, ramelteon, which was developed by Takeda Pharmaceutical Company Ltd. This investigation was also approved and supported by the funder. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: KN KH. Performed the experiments: KN. Analyzed the data: KN. Contributed reagents/materials/analysis tools: KN. Wrote the paper: KN KH. Decision on the present publication: KH.